uniQure N.V. (QURE) · Sep 29, 2026 · Other events
Above the bar — 36-month cUHDRS slowing of 80%; TFC slowing of 67%
uniQure’s new Huntington’s clinical data reinforce the BLA case with strong 36-month results, though missing external-control data weaken the four-year comparison.
uniQure is at the regulatory handoff for its Huntington’s gene therapy: the company submitted its BLA on September 2, 2026, after aligning with the FDA on an accelerated-approval path, while the confirmatory study remains the route to full approval.
The expanded 36-month dataset strengthens the regulatory story. Adding three high-dose patients produced 80% slowing on cUHDRS and 67% on TFC, the functional measure that anchors the confirmatory study. 〔0〕 This is better than merely preserving the prior signal: it gives the already-submitted BLA a larger supporting dataset, although the new results were not included in that submission.
The four-year read is directionally encouraging but statistically uneven. At 48 months, TFC showed a nominally significant 61% slowing, while the prespecified cUHDRS endpoint showed 44% slowing that was not statistically significant. 〔1〕 The apparent persistence of functional benefit is useful evidence for durability, but it is not a clean confirmation across both measures.
The external-control comparison is the main qualification. Missing data reached 53% in the updated matched controls at 48 months, and faster-progressing patients were more likely to disappear from follow-up. 〔2〕 Using an earlier control dataset improved the reported 48-month effect, but that sensitivity also shows how dependent the long-term percentages are on comparator construction. The 36-month result is therefore the cleaner regulatory signal; the 48-month result is supportive, not definitive.
Safety remains manageable but not immaterial. The company says the procedure-related adverse events resolved, while five high-dose participants, or 17%, experienced treatment-related serious events involving central nervous system inflammation, all of which resolved. 〔3〕 That does not overturn the efficacy read, but it remains part of the approval and confirmatory-study burden.
Bottom line: This update clears the practical bar for a stronger BLA narrative: the expanded three-year data are robust and the benefit appears to persist functionally into year four. The result is meaningfully supportive, but the non-significant four-year primary endpoint and fragile external control keep it from being a clean, conclusive validation of durability.
FDA review of the submitted BLA; confirmatory study design
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!